Compare Twist Bioscience Corp (TWST) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Western Digital Corp — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.26B), while Western Digital Corp trades at $476.5 (market cap $173.88B). The key difference: Western Digital Corp is far larger — about 21.1× Twist Bioscience Corp's market cap, and Western Digital Corp pays a 0.12% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | WDC | |
|---|---|---|
Market Cap | $8.26B | $173.88B |
Sector | Health | Technology |
52-Week High | $153.10 | $746.23 |
52-Week Low | $24.16 | $95.03 |
Enterprise Value | $8.18B | $173.35B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Western Digital (WDC) trades at $477.30, up 2.1% on the day, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock exhibits robust fundamentals with a net income margin of 71.97% and ROE of 131.02%, supported by positive cash flow trends. Recent news highlights AI-driven storage demand and institutional accumulation, such as CalSTRS increasing its stake by 64,424.3% in Q2 2026 (SEC filing, September 7, 2026).
Outlook remains favorable with a consensus price target of $676.70 (72% buy ratings), though risks include high valuation multiples and cyclical industry exposure. Earnings growth from AI data expansion is a key catalyst, but investor caution is warranted near all-time highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
